Additional file 1 of Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study
Creators: name: Du, Xiaoyue
name: Wen, Shaodi
name: Shi, Run
name: Xia, Jingwei
name: Wang, Ruotong
name: Zhang, Yihan
name: Pan, Banzhou
name: Wu, Xiaoliu
name: Zhu, Wei
name: Feng, Jifeng
name: Wang, Xin
name: Shen, Bo
Publisher: name: figshare
Year: 2023
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1: Supplement Fig. 1. Process of research and experimental gating strategy. (A) Diagram of peripheral blood sample collection, treatment and treatment efficacy evaluation. (B) Flowchart of study design. (C) Flow cytometry gating strategy. Leukocytes were first identified based on CD45 expression. Lymphocytes were identified based on forward (size) and side (granularity) scatted characteristics. Expression of CD3 identified Total T cells (CD3+), and were further subdivided based on CD4 and CD8 expression into TH(CD3+CD4+) and CTL(CD3+CD8+) cells. Expression of HLA-DR and CD56 identified the Activated T cells (HLADR+) and NKT cells (CD56+). Expression of CD19 / CD56 but do not express CD3 were identified as B cells (CD3-CD19+) and NK cells (CD3-CD56+). Supplement Fig. 2. Differences between DCB and NDB groups at baseline and post ICB treatment in the training. Nonparametric Mann-Whitney test was used for comparisons (using continuous variables). Durable clinical benefit; NDB, None durable benefit; NK, natural killer; NKT, natural killer T; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; NSE, neuron-specific enolase. Supplement Fig. 3. Overall population Kaplan–Meier curves for PFS(A) and OS(B). DCB and NDB group Kaplan–Meier curves for (C)PFS and (D)OS. P Values were calculated by log-rank statistics. Durable clinical benefit; NDB, None durable benefit; PFS, progression-free survival; OS, overall survival. Supplement Fig. 4. Kaplan–Meier curves forPFS. P Values were calculated by log-rank statistics. Supplement Fig. 5. Kaplan–Meier curves for OS. P Values were calculated by log-rank statistics. Supplement Fig. 6. Relationship between infiltrating lymphocytes and prognosis in NSCLC patients with TCGA. Whole-transcriptome RNA-seq data for 337 NSCLC cases and their corresponding clinical data were downloaded from the TCGA database ( https://portal.gdc.cancer.gov/ ). Immuno-infiltrating cells were calculated with the xCell R package. Patients’ parameters were categorized by optimal cut-off values (Low / High group), The survival curve was plotted using the Kaplan–Meier method and the log rank test was used to determine statistical significance; p&lt;0.05 was considered statistically significant. The Cancer Genome Atlas Program, TCGA; Central memory T cells, Tcm; Effector memory T Cells, Tem; Helper T cell, TH. Supplementary Table 1. Clinical characteristics of Training set and Validation set. Supplementary Table 2. Flow cytometry antibody list. Supplementary Table 3. Training set baseline peripheral blood parameters. Supplementary Table 4. Training set patients’ peripheral blood parameters at Δ6W, Δ12W. Supplementary Table 5. The association between patient peripheral blood parameters and treatment response. Supplementary Table 6. Multivariable Logistic regression models for DCB. Supplementary Table 7. Multivariable Logistic regression of DCB. Supplementary Table 8. Univariable and Multivariable Cox regression analysis of Progression free survival. Supplementary Table 9. Univariable and Multivariable Cox regression analysis of Overall survival. Supplementary Table 10. Median months of PFS and OS in each group. Supplementary Table 11. Univariable Cox regression of Progression free survival. Supplementary Table 12. Univariable Cox regression of Overall survival.